NCT01339988UnknownPhase 4
Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Enrollment
- 10
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age. Growth failure, decline in cognitive function, and endocrine abnormalities have all been described. Good outcomes can be achieved with alkylating agents only as a preparative regimen. This plan will use a combination of busulfan and cyclophosphamide (Bu/Cy) with or without antithymocyte globulin (ATG) to reduce the late toxicities of therapy that includes TBI.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- — to 21 Years (Child, Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Suitable cord blood from matched unrelated or related donor.
- •Cardiac (Echo/EKG): shortening fraction ≥ 27%
- •Electrolytes within normal CCHMC limits.
- •Pulmonary function tests: DLCO ≥ 50%
- •Renal: creatinine clearance/GFR ≥ 60 ml/minute/1.73m2
- •Lumbar puncture: no leukemic infiltrate.
- •CBC: ANC ≥ 1000ml and unsupported platelet count of ≥ 50,000/ml
- •Documented HSV and CMV titers, Hepatitis B surface antigen, Hepatitis C by serology, HIV by serology: all negative.
- •Hepatic transaminases < 2.5x normal; Total bilirubin < 2 mg/dl Patients who do not meet above organ function criteria (liver, cardiac, renal), due to the presence of a tumor compromising these organs, may have exception made for these criteria and remain eligible for treatment plan after consultation with Program Director of Blood and Marrow Transplant
Exclusion Criteria
- •Patients with neoplastic or non-neoplastic disease of any major organ system that would compromise their ability to withstand the pre-transplant conditioning regimen.
- •Patients with uncontrolled (culture or biopsy positive) infections requiring intravenous antivirals, antibiotics, or antifungals. Patients on prolonged antifungal therapy with a history of fungal infection should be considered for a non-myeloablative protocol.
- •Patients who are pregnant or lactating. Patients of childbearing potential must practice an effective method of birth control while participating on this treatment plan.
- •HIV seropositive patients
Arms & Interventions
Busulfan/Cyclophosphamide
Experimental
Intervention: Busulfan/Cyclophosphamide (Drug)
Outcomes
Primary Outcomes
Overall survival
Time Frame: Five years
Secondary Outcomes
- Disease free survival(Five years)
Investigators
Similar Trials
Recruiting
Not Applicable
TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological DiseasesHematopoietic Stem Cell TransplantationMalignant Hematological DiseasesNCT05929092The First Affiliated Hospital of Soochow University40
Recruiting
Not Applicable
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal CarcinomaIntensity-Modulated RadiotherapyNasopharyngeal CarcinomaNCT05994170Zhongshan People's Hospital, Guangdong, China454
Suspended
Phase 2
ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDSMyelodysplastic SyndromeAcute LeukemiaNCT01709396Ottawa Hospital Research Institute20
Completed
Phase 1
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune DisordersSystemic Lupus ErythematosusAutoimmune DiseasesSystemic SclerosisDermatomyositisJuvenile Rheumatoid ArthritisNCT00010335Fred Hutchinson Cancer Center6
Terminated
Phase 1
Image Guided Reirradiation of High-grade GliomaMalignant GliomaGlioblastomaNCT02025231Rigshospitalet, Denmark31